Pharmaceutical Segment is the largest segment driving the growth of Anti-Neprilysin Market
Anti-Neprilysin Market |
The global Anti-Neprilysin Market
is estimated to be valued at US$ 1,263.3
Mn in 2023 and is expected to exhibit a CAGR of 4.6% over the forecast period 2023 to 2030, as highlighted
in a new report published by Coherent Market Insights.
Market Overview:
Anti-Neprilysin drugs are mainly
used for the treatment of heart failure. They work by blocking the enzyme
neprilysin and increasing levels of natriuretic peptides which help relax blood
vessels and sodium excretion from the body.
Market key trends:
One of the major trends in the
anti-neprilysin market is the increasing prevalence of heart failure worldwide.
As per the American Heart Association, over 6 million adults in the U.S. suffer
from heart failure. The condition is more common among elderly people. With
rising life expectancy, the number of people suffering from heart failure is
expected to increase significantly in future, thereby driving the demand for
anti-neprilysin drugs for its treatment and management.
Market key trends:
The anti-neprilysin market
iswitnessinghigh growth owing to the rising prevalence of heart failure across
the globe. As per stats, nearly 6.2 million American adults suffer from heart
failure. Rising geriatric population is another factor contributing to the
growth of this market as aged people are more susceptible to chronic heart
conditions. Moreover, drugmakers are actively investing in R&D activities
to develop better anti-neprilysin drugs with improved efficacy and safety
profiles which is bolstering market expansion.
SWOT Analysis
Strengths: Existing drugs have
demonstrated efficacy in improving symptoms in heart failure patients. Drugs
also help in reducing mortality rates.
Weaknesses: High development
costs involved due to lengthy clinical trials. Potential side effects of drugs
like hypotension and angioedema.
Opportunities: Rising incidences
of heart diseases creates demand for improved treatment options. Several
pipeline drugs are under development.
Threats: Patent expiries of major
drugs resulting in lower profits. Price controls and regulatory hurdles also restrict
growth.
Key Takeaways
The global
anti-neprilysin market is expected to witness high growth, exhibiting CAGR
of 4.6% over the forecast period, due to increasing geriatric population
suffering from chronic heart ailments.
Regionally, North America
accounts for the largest share in the anti-neprilysin market due to growing
prevalence of heart diseases. Europe holds second largest market share owing to
rising healthcare spending. Asia Pacific exhibits potential growth due to
improving access to healthcare facilities.
Key players operating in the anti-neprilysin market are BIOPROJET,
Novartis AG, Pharmaleads SA, Theravance Biopharm, Cipla Inc, Oceanic Pharmachem
Pvt. Ltd. BIOPROJET leads the market with its blockbuster brand Entresto used
for treatment of chronic heart failure. Novartis also has a significant share
with its product LCZ696.
Read more
https://www.dailyprbulletin.com/anti-neprilysin-market-growth-size-share-growth-outlook-2023/
Comments
Post a Comment